Influence of intramuscular application of autologous conditioned plasma on systemic circulating IGF-1

Gert Schippinger 1,2, Karl Oettl 3, Florian Fankhauser 2, Stefan Spirk 1,4, Wolfgang Domej 5 and Peter Hofmann 1,4
1 Human Performance Research Graz, University of Graz and Medical University of Graz; 2 Sportchirurgie Plus Graz; 3 Institute of Physiological Chemistry, Medical University of Graz; 4 Institute of Sports Science, University of Graz; 5 Department of Internal Medicine, Medical University of Graz, Austria

Abstract
Platelet-rich plasma (PRP) to increase levels of platelets and growth factors has been used for the treatment of sports injuries suggesting to improve healing and regeneration. This method offers some potential especially for elite athletes. However, the insulin like growth factor-1 (IGF-1) is prohibited by the World Anti Doping Agency and, in addition, there may be a possible link between increased levels of IGF-1 and cancer risk. Aim of the study was to evaluate a systemic increase of IGF-1 after local intramuscular administration of PRP in young healthy moderately trained male subjects. Blood samples were drawn and PRP preparation was performed by means of centrifugation. Enriched plasma was injected into the gluteus muscle. Venous blood was collected and serum prepared before as well as after 0.5, 3 and 24 hours after PRP administration. IGF-1 analysis was performed applying an ELISA test kit. No significant systemic increase of mean IGF-1 was found after the PRP injection. Only one subject showed an increase after 24 h, but all IGF-1 values were found within reference limits. We conclude that a single intramuscular application of PRP does not significantly increase systemic IGF-1 levels. Therefore, a single application of PRP is safe with respect to systemic IGF-1 response and cancer risk and this should be allowed for treatment of muscle injuries in elite athletes.

Key words: Platelet rich plasma, intramuscular application, IGF-1, cancer risk, doping.

Introduction
Recently, an increased trend has emerged in the use of autologous blood products in an effort to promote healing in a variety of applications such as muscle injuries, chronic tendinopathies and cartilage degeneration (Baltzer et al., 2009; Banfi et al., 2006; Castricini et al. 2011; Creaney and Hamilton 2008, Volpi et al. 2010). The potentially beneficial method described is the homologous local application of concentrated platelets (Baltzer et al., 2009; Banfi et al., 2006; Mishra and Pavelko, 2006) also known as platelet rich plasma (PRP) (Foster et al., 2009). Several preliminary studies showed possible benefits of this therapeutic PRP application (Banfi et al., 2006; Baltzer et al., 2009; Mishra and Pavelko, 2006; Sánchez et al., 2009). However, the evidence is not supported yet (Arnoczky et al., 2009, Mishra and Pavelko, 2006; Sánchez et al., 2009).

The PRP method and its application
PRP can be defined as plasma containing a concentration of platelets that is above the concentration found in whole blood. Platelet-rich plasma, with a platelet concentration of at least 10^9 platelets/l, is very likely associated with the enhancement of healing (Marx, 2004). Platelet-rich plasma contains up to 4 times the concentration of platelets found in whole blood. The basic bioactive factors identified in platelets are the transforming growth factor–β (TGF-β), the platelet-derived growth factor (PDGF), the insulin-like growth factors (IGF-1, IGF-2), the fibroblast growth factor (FGF), the epidermal growth factor, the vascular endothelial growth factor (VEGF), and the endothelial growth factor (EGF). These cytokines play important roles in cell proliferation, chemotaxis, cell differentiation, and angiogenesis (Foster et al., 2009).

Although debate continues regarding the potential benefit of PRP to improve bone healing (Griffin et al., 2009; Ranly et al., 2007) a growing body of laboratory evidence supports the use of PRP injections for the treatment of muscle and tendon injuries (Sánchez et al., 2007, 2009b; Wright-Carpenter et al., 2004). However, a recent randomized controlled study by Castricini et al. (2011) did not support the use of autologous platelet-rich fibrin matrix in the treatment of rotator cuff injury.

Sports injuries to muscle tissue are very frequent due to a direct blow or tearing of the muscle. Early recovery is crucial for athletes and therefore therapies pushing the healing process are very attractive (Lopez-Vidriero et al., 2010). As in other parts of the body, healing is dependent upon the vascularity of the tissue (Yokota et al., 2008). The speed of recovery depends on the severity of the injury, the post injury treatment, and the patient’s inherent ability to heal soft tissue injuries. Several techniques have been employed in an effort to shorten return to play intervals. Platelet-rich plasma has been suggested as a potential intervention for athletes with acute muscular injuries (Lopez-Vidriero et al., 2010). One in vitro study suggests that growth factors may influence muscle regeneration after injury (Kasemkjwattana et al., 2000). Platelet-rich plasma treatment after an acute muscular injury may benefit the athlete by decreasing the time of recovery; however, there are no randomized controlled human studies regarding the use of PRP for muscle injuries.

Beside possible beneficial effects of PRP, several
concerns have been raised about undesirable side effects. Particular attention is focused on IGF-1 because of its potential doping (Tentori and Graziani 2007) and carcinogenic effect (Grimberg and Cohen, 2000; Grimberg, 2003, LeRoith and Roberts, 2003; Lann and LeRoith, 2008; Rowlands et al., 2009).

Banfi et al. (2006) already investigated the systemic response of several growth factors after a single PRP application, however, these authors did not investigate IGF-1.

IGF-1
IGF-1 has at least three isoforms, whereas the isoform IGF-1Ea is known to stimulate terminal differentiation of muscle cells into myotubes and promote stem cell-mediated muscle regeneration, whereas MGF (isoform IGF-1Ec) is damage sensitive, controls local tissue repair and is more potent than IGF-1Ea at causing hypertrophy. MGF is rapidly degraded in the serum (Philippou et al., 2008; Rowlands et al., 2009).

IGF-1 and carcinogenesis
In reference to carcinogenesis, Creaney and Hamilton (2008) and Marx (2004) suggested that growth factors act on cell surface receptors, do not enter the cell, and do not cause DNA mutation. Therefore, from their point of view, no plausible mechanism can be described by which growth factors result in neoplastic development. Despite no direct evidence published so far, there are some indications that elevated IGF-1 may have some relationship to cancer development. Grimberg and Cohen (2000) and Grimberg (2003) concluded in their review papers that multiple large case-control studies have reported positive associations between high circulating levels of IGF-1 and risk for different types of cancer and they critically mentioned that this hypothesis is worth for further examinations through mechanistic studies. A systematic review and meta-regression analysis by Renehan et al. (2004) showed that concentrations of circulating IGF-1 and IGFBP-3 (an IGF binding protein) were associated with an increased risk of common cancers, but associations were modest and varied between sites.

IGF-1 and doping issues
The latest statement of the WADA 2011 has deleted the prohibition of intramuscular injection of platelet-derived preparations (e.g. PRP, “blood spinning”) (WADA, 2011). All routes of administration require a declaration of use in accordance with the International Standard for Therapeutic Use Exemptions (TUE).

The fact that IGF-1 is a prohibited substance in the prohibited S2 section by the WADA is an important concern which has provoked discussions among orthopaedic sports medicine practitioners. A detailed analysis of the prohibited S2 section reveals that besides IGF-1 several growth factors affecting muscle, tendon or ligament protein synthesis/degradation, vascularization, energy utilization, regenerative capacity or fibre type switching are prohibited with the exception of platelet-rich therapies applied intramuscularly (WADA, 2011) (Engebretsen et al., 2010).

Overall, basic scientific research supports the opinion that PRP is unlikely to provide a potent ergogenic aid for the following reasons:

• The doses of IGF-1 in PRP are subtherapeutic in terms of producing systemic anabolic actions by a factor of 500 (300 ng versus 160 µg) (Creaney and Hamilton, 2008). Several commercial PRP systems such as ACP, GPS, and PRGF have been shown not to increase IGF-1 over normal circulating blood levels (Conway et al., 2006; Eppley et al., 2004; Buhr and Siekmann, 2009; Sánchez et al., 2007; Anitua et al., 2005).

• The availability of most IGF-1 is modulated by a binding protein (IGFBP-3) and only 1% of the total IGF-1 released from the PRGF is unbound, and therefore biologically available and active, ready to bind to receptors (IGF-1Rs) inducing biological outcomes. In addition, the unbound IGF-1 has too short a half-life to be able to exert systemic effects (10 min versus 16 h for the bound form) (Foster et al., 2009).

• The isoform IGF-1Ea found in PRP is not the isoform principally responsible for skeletal muscle hypertrophy (IGF-1Ec/MGF) and may not have the same performance-enhancing effects as skeletal muscle-derived IGF-1Ea (MGF) (Creaney and Hamilton, 2008).

Although it is unlikely that a single PRP injection systematically increases IGF-1, this important growth factor has, to our knowledge, not been investigated yet in this regard.

The aim of the study was to investigate possible systemic effects of intramuscularly applied PRP on serum IGF-1 levels in healthy subjects to exclude potential cancer risks and to clarify doping issues. In line with the literature we hypothesized no systemic IGF-1 effect after one single PRP injection. This might be of relevance for top level athletes and non-athletes alike, as neither the increased risk of cancer promotion nor the risk for a positive doping test by a distinct systemic increase of IGF-1 would exist.

Methods
Ten 23 ± 1.5 years old healthy trained male subjects (VO2max: 52.0 ± 11.1 ml·kg⁻¹·min⁻¹; body mass: 78.7 ± 9.3 kg, height 1.84 ± 0.08 m) were investigated. Written informed consent was obtained from all subjects and the study was approved by the local ethics committee (No.: 21-160ex 09/10).

Prior to taking blood, 1 ml of ACD-A (Anticoagulant Citrate Dextrose Solution, NoClot 400™, Cytosol Laboratories, INC) was withdrawn into the outer syringe of an ACP Double syringe system (Arthrex®). Then 9 ml of venous blood was withdrawn with a butterfly cannula of the cubital vein. The blood was processed at 1500 rpm for 5 minutes within a centrifuge (Hettich Rotofix 32A) to
separate plasma from erythrocytes and leukocytes and the plasma transferred to the smaller syringe by pulling the according (small) plunger. Thereafter, 2.5 ml of autologous conditioned plasma (ACP) was injected into the right gluteus maximus of each subject.

According to the manufacturer’s reference the ACP product consists of a 1.6 fold increase of platelets (unpublished white paper, Arthrex®), a 2-6 fold increase in the growth factors EGF, VEGF, TGF-β1, TGF-β2, PDGF-AB, PDGF-BB, as well as a 10% increase in IGF-1 (Engebretsen et al. 2010).

Venous blood samples were drawn from the same cubital vein and serum was prepared to determine IGF-1 levels before ACP administration, after 30 minutes, 3 hours and 24 hours, respectively. Samples were stored at -20°C until further processing. All subjects were requested to abstain from any exercise at least two days prior to testing and during the observation period.

Serum IGF-1 was measured in duplicate using the R&D Quantikine ELISA testkit for human IGF-1 (Biomeda, Vienna, Austria) following the manufacturer’s instructions. Intra-assay precision was found within the limits described by the manufacturer to be between 3.5 and 4.3% (Human IGF-1 immunoassay, Quantikine, R&D Systems).

The actual number of platelets was not directly measured but the manufacturer’s specification suggest a 1.6 fold increase of platelets compared to whole blood (unpublished white paper, Arthrex®).

**Statistical analysis**

Measures are reported as means (±SD) and data were tested as being normally distributed (Kolmogorov-Smirnov-test; Winstat, Calmia Corp., USA). Comparisons between pre and post IGF-1 levels were performed by means of repeated measures ANOVA. A p-value < 0.05 was considered to be significant. The required sample size of 10 subjects was calculated a-priori by G*Power analysis (Faul et al., 2007) (using an assumed large effect size of 0.4 (Cohen, 1988), an α-level of 0.05 and a power of 0.8) to simulate a meaningful elevation of IGF-1 above mean values for this age group (Brabant et al., 2003).

**Results**

Mean pre application values of IGF-1 were found at the lower limit of age related norms (161 ± 27 µg·l⁻¹) as shown by Brabant et al. (2003). The application of ACP did not influence mean IGF-1 values after 30 minutes (157 ± 29 µg·l⁻¹), 3 (159 ± 25 µg·l⁻¹) and 24 hours (161 ± 38 µg·l⁻¹), receptively. There was no significant difference detectable between groups (repeated measures ANOVA p-value > 0.05). The individual time courses of IGF-1 were essentially the same in all subjects except one (Figure 1), who presented an increase of IGF-1 from 171 pre ACP conditions up to 220 µg·l⁻¹ after 24 hours post ACP application. All single values were within the age related means for IGF-1 in this age group.

**Discussion**

A single intramuscular ACP administration in young healthy trained subjects had no effect on circulating IGF-1 values. Only one subject showed an increase from pre ACP conditions to post ACP injection after 24 hours. However, this change was within reference limits for this age group (Brabant et al., 2003).

Several studies have suggested that PRP may be advantageous in sports medicine, but there are little data aside from small case series to support this hypothesis.

The majority of performed human studies are level 4 and 5 studies, which demonstrated the efficacy of PRP in treating tendinopathies (Anitua et al., 2005; Buhr and Siekmann, 2009; Conway and Roberts, 2003; Lann and LeRoith, 2008; Rowlands et al., 2009a; 2009b). There is a need for prospective, randomized controlled double-blind studies that meet the requirements for properly powered studies. Despite this fact the authors believe this technology may see new exciting developments in the next decades.

**IGF-1 and carcinogenesis**

One concern may be a potential carcinogenic effect of IGF-1 provided that PRP application results in a sustained increase in IGF-1 levels above normal. Several authors concluded positive associations between high circulating levels of IGF-1 and risk for different types of cancer (Grimberg and Cohen, 2000; Grimberg, 2003, LeRoith and Roberts, 2003; Lann and LeRoith, 2008; Rowlands et al., 2009; Chen et al., 2009). A single intramuscular PRP administration however, did not show an increase in circulating IGF-1 levels after 30 minutes and 3 and 24 hours post application. From this point of view, a single PRP injection is suggested to be a safe method of treatment at least as applied in our study. Although multiple injections were not specifically examined in this study, the lack of increase in IGF-1 seen in the 10 subjects combined with the fact that most PRP systems do not concentrate IGF-1 (Anitua et al., 2005; Buhr and Siekmann, 2009; Conway et al., 2006; Eppley et al., 2004; Sánchez et al., 2007) would not raise additional concerns regarding carcinogenic effects of IGF-1 increase as a result of multiple injections.

**IGF-1 and doping issues**

An important issue is the fact that administration of PRP
in sports medicine was critically discussed to by the WADA, particularly because of concerns regarding the IGF-1 content of such preparations and its potential for abuse as performance-enhancing agents. It has been shown recently that PRP products are unlikely to increase IGF-1 levels systemically, although not experimentally proven (Creaney and Hamilton, 2008). Still, it has to be clearly stated that exogenous IGF-1 administration apart from PRP as performance enhancing growth hormone is still banned by the WADA anti-doping code (section S2).

Growth hormones have gained popularity in the last two decades due to the availability of the recombinant forms and are now largely used in the sports world (Saugy et al., 2006; Sonkens, 2001; Stay et al., 2004). Nowadays, athletes such as cyclists, swimmers, power lifters and body builders are suspected to use recombinant GH or IGF-1 for desired anabolic effects (Stay et al., 2004; Saugy et al., 2006; Sonkens, 2001).

The current study has shown that the standardized method of one single intramuscular PRP administration does not increase systemic IGF-1 levels and is therefore suggested as an ineffective means to gain systemic effects. This is in line with Creaney and Hamilton (2008) who stated that PRP is unlikely to be a potent ergogenic aid because the unbound IGF-1 has too short a half-life to be able to exert systemic effects and the doses of IGF-1 in PRP are subtherapeutic in terms of producing systemic anabolic actions even without a delay in growth factor release as used in our study. Similarly, Volpi et al. (2010) concluded from their study, that PRP-based local therapy could influence systemic homeostasis and antidoping evaluations, but, in their opinion, does not represent a doping substance itself.

A limit of the study may be the small sample size and the use of IGF-1 measures only instead of various growth factors (Banfi et al., 2006). An additional limit may be the fact that the actual content of IGF-1 was not measured in our applied ACP product. Previous studies confirmed a 2-3 fold increased platelet concentration and increased growth factors including IFG-1 in the ACP product (unpublished white paper – Athrex®). Additionally, from our data it cannot be ruled out that a different metabolization may be evident in injured muscle tissue.

**Conclusion**

Several concerns regarding IGF-1 application such as a possible carcinogenic effect and more importantly doping issues in athletes do exist. The PRP method offers some interesting aspects for the treatment of injured athletes to promote and accelerate the physiological healing process and functional recovery and effective from January 2011 a local intramuscular application is allowed by the WADA code.

Our data showed no increase of systemic IGF-1 levels after one single local intramuscular administration of PRP. Therefore, professional athletes and non-athletes alike can benefit from such a treatment option for muscle injuries and related sports injuries without an increased risk of cancer. However, more studies are warranted to provide definitive evidence to guide surgeon’s decision making regarding the appropriate use for PRP products.

**Acknowledgements**

The authors would like acknowledge the assistance of Julia Kööpf for her statistic analysis.

**Competing interests:** Each author certifies that he has no commercial associations (e.g. consultancies, stock ownership, equity interest, patient/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted paper.

**Funding:** This study was supported by Athrex® which is a company that markets a system for preparing PRP (ACP®) for therapeutic use.

**References**


Key points

- There is no increase of systemic IGF-1 levels after a single local intramuscular administration of PRP.
- Professional athletes and non-athletes alike can benefit from such a treatment option for muscle injuries and related sports injuries without an increased risk of cancer.
- More studies are warranted to provide definitive evidence to guide surgeon’s decision making regarding the appropriate use for PRP products.

AUTHORS BIOGRAPHY

Gert SCHIPPINGER

Employment
Professor at Human Performance Research Graz, University and Medical University Graz.

Research interest
Oxidative stress, sports injury and biological treatment options, arthroscopic surgery

E-mail: gert.schippinger@uni-graz.at

Karl OTTL

Employment
Associate professor for pathological chemistry at the Institute for Physiological Chemistry, Medical University of Graz

Degree
Dr. rer. nat.

Research interest
Oxidative stress in exercise and disease, Albumin chemistry and function in liver disease, Analytics of physiologically and clinically relevant compounds

E-mail: karl.oettl@medunigraz.at

Florian FANKHAUSER

Employment
Private practice for trauma and orthopaedic surgery “Sportchirurgieplus” Lecturer for physiotherapy at FH Joanneum Graz

Degree
MD, PhD

Research interest
Oxidative stress, sports injury, arthroscopic surgery

E-mail: florian.fankhauser@sportchirurgieplus.at
Stefan SPIRK
Employment
Student Assistant at Human Performance Research Graz, University Graz, Student of Sport Science, Institute of Sport Science University of Graz
Research interest
Sports injury, performance diagnostics and training
E-mail: s.spirk@uni-graz.at

Wolfgang DOMEJ
Employment
Professor for Sport medicine at Human Performance Research Graz, University and Medical University Graz and Pulmonologist Clinical Department of Pulmonology
Degree
MD
Research interest
High-altitude physiology and medicine, hypoxic chamber technology, respiration at moderate to high altitude, high-altitude tolerance and intolerance, ergometry in hypoxic conditions, prae-acclimatisation and training under hypoxic conditions, chronic disease states and altitude exposure, expeditions medicine high-altitude pulmonary hypertension, hypoxic ventilatory and vascular response, chronic hypoxic vascular remodelling
E-mail: wolfgang.domej@medunigraz.at

Peter HOFMANN
Employment
Professor at Human Performance Research Graz, University and Medical University Graz and Institute of Sports Science, University of Graz
Degree
Dr. rer. nat.
Research interest
Exercise testing and performance diagnostics, exercise prescription and training
E-mail: peter.hofmann@uni-graz.at

Univ. Prof. Dr. Gert Schippinger
Human Performance Research Graz, University of Graz and Medical University of Graz, Max-Mell-Allee 11, A-8010 Graz, Austria